NCT05663710View on ClinicalTrials.gov

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Advanced CancerClear Cell Renal Cell Carcinoma
Interventions
DRUG

177Lu girentuximab

Given by IV (vein)

DRUG

Nivolumab

Given by IV (vein)

DRUG

Cabozantinib

Given by PO

DRUG

ArabinoFuranosylGuanine [18F]F-AraG

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Telix Pharmaceuticals Limited

UNKNOWN

collaborator

United States Department of Defense

FED

lead

M.D. Anderson Cancer Center

OTHER